Market Research Logo

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018'; Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 26 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.

The report 'Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018' outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 6, 5, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Type 2 Diabetes, Lung Adenocarcinoma, Ovarian Cancer, Bladder Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Cancer, Obesity, Recurrent Glioblastoma Multiforme (GBM), Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Constipation, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, High-Grade Glioma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Lymphoma, Metastatic Biliary Tract Cancer, Nasopharyngeal Cancer, Non-Alcoholic Steatohepatitis (NASH), Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Abbisko Therapeutics Co Ltd
Amgen Inc
ArQule Inc
Bayer AG
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
Genosco Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Incyte Corp
Ionis Pharmaceuticals Inc
Johnson & Johnson
Merrimack Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Novartis AG
Principia Biopharma Inc
Tasly Pharmaceutical Group Co Ltd
Vichem Chemie Research Ltd
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ABSK-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-9931 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
derazantinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golvatinib tartrate + lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-81442 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-62079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-463588 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MM-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rogaratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSLB-1344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 14, 2018: NGM Bio Announces Results From Phase 2 Study Of NGM282 In Nash Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
Apr 13, 2018: NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis
Mar 23, 2018: Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
Mar 15, 2018: Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Mar 15, 2018: ArQule to Present Data on Derazantinib
Mar 12, 2018: Grupo Biotoscana Announces New Initiatives for LENVIMA
Mar 12, 2018: NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
Mar 08, 2018: Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease
Feb 16, 2018: UK NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Feb 15, 2018: Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet
Feb 10, 2018: Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in the Lancet
Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)
Jan 26, 2018: NICE Issues Technology Appraisal Guidance on Lenvatinib with Everolimus for Previously Treated Advanced RCC
Jan 25, 2018: Janssen to Present data on Erdafitinib at Prostate and Urothelial Cancers at ASCO GU 2018
Jan 22, 2018: Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) In Hepatocellular Carcinoma Based on Independent Imaging Review at ASCO-GI
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abbisko Therapeutics Co Ltd, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by ArQule Inc, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Blueprint Medicines Corp, H1 2018
Pipeline by Eddingpharm Inc, H1 2018
Pipeline by Eisai Co Ltd, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Genosco Inc, H1 2018
Pipeline by H3 Biomedicine Inc, H1 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Merrimack Pharmaceuticals Inc, H1 2018
Pipeline by NGM Biopharmaceuticals Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Principia Biopharma Inc, H1 2018
Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
Pipeline by Vichem Chemie Research Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report